Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam
Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam
复制标题
肠杆菌科细菌的药敏试验：头孢他啶/阿维巴坦的纸片含量和 Kirby-Bauer 断点测定
DOI：
10.1186/s12866-019-1613-5
复制
发表时间：
2019-11
期刊：
影响因子：
4.2
通讯作者：
Xu Ying
中科院分区：
文献类型：
--
作者：
Yang Xianggui;Wang Dan;Zhou Qin;Nie Fang;Du Hongfei;Pang Xueli;Fan Yingzi;Bai Tingting;Xu Ying
头孢他啶/阿维巴坦(CAZ/AVI)抗菌活性的检测对于耐碳青霉烯类肠杆菌科细菌(CRE)的快速生长至关重要。结果采用微量肉汤稀释法对临床分离的386株肠杆菌科细菌(肺炎克雷伯菌188株、大肠埃希菌122株、阴沟肠杆菌76株)进行了CAZ/AVI药敏试验。其中产超广谱β内酰胺酶(−)54株，阳性(ESBL(+))104株，CRE 228株。287个菌株对CAZ/AVI敏感，99个菌株对CAZ/AVI抗性。同时，为获得头孢他啶的最佳含量(30μg)，用K-B法测定了4种不同含量(0μg、10μg、25μg、50μg)的头孢他啶(30μg)头孢他啶的抑菌圈直径。以微量肉汤稀释法解释作为判断敏感或耐药的标准，然后对Kirby-Bauer法与微量肉汤稀释法进行相关性分析。结果表明，30μg/50μg纸片的抑菌圈直径，敏感菌株为20.5 mm~31.5 mm，抗性菌株为8.25 mm~21.5 mm。30μg/25μg纸片抑菌圈直径，敏感菌株19.7 mm~31.3 mm，抗性菌株6.5 mm~19.2 mm。抑菌圈直径30μg/10μg盘，敏感菌株19.5 mm~31 mm，抗性菌株6.5 mm~11 mm。结论30μg/50μg、30μg/25μg、30μg/10μg CAZ/AVI纸片对CAZ/AVI抗菌活性的测定有显著统计学差异，但对于30μg/50μg纸片，敏感菌株(最小为20.5 mm)和耐药菌株(最大为21.5 mm)之间存在截面积。对于30μg/25μg纸片，很难区分敏感菌株(最小为19.7 mm)和抗性菌株(最大为19.2 mm)，因此30μg/10μg CaZ/AVI纸片更有利于抗菌活性的测定。
BackgroundDetection of ceftazidime/avibactam (CAZ/AVI) antibacterial activity is absolutely vital with the rapid growth of carbapenem resistantEnterobacteriaceae(CRE). But now, there is no available automated antimicrobial susceptibility testing card for CAZ/AVI, so Kirby-Bauer has become an economical and practical method for detecting CAZ/AVI antibacterial activity againstEnterobacteriaceae.ResultIn this study, antimicrobial susceptibility testing of CAZ/AVI against 386Enterobacteriaceae(188Klebsiella pneumoniae, 122Escherichia coli, 76Enterobacter cloacae) isolated from clinical patients was performed by broth microdilution. Of the 386 strains, 54 extended spectrum β lactamases negative (ESBL(−)), 104 extended spectrum β lactamases positive (ESBL(+)), 228 CRE. 287 isolates were susceptible to CAZ/AVI and 99 isolates were resistant to CAZ/AVI. At the same time, to obtain optimal content avibactam (AVI) disk containing ceftazidime (30 μg), inhibition zone diameter of four kinds of ceftazidime (30 μg) disk containing different AVI content (0 μg, 10 μg, 25 μg, 50 μg) were tested by Kirby-Bauer method. The microdilution broth method interpretation was used as the standard to estimate susceptible or resistance and then coherence analysis was carried out between Kirby-Bauer and broth microdilution. The result shows the inhibition zone diameter of 30 μg/50 μg disk, susceptible isolates: 20.5 mm–31.5 mm, resistance isolates: 8.25 mm–21.5 mm. The inhibition zone diameter of 30 μg/25 μg disk, susceptible isolates: 19.7 mm–31.3 mm, resistance isolates: 6.5 mm–19.2 mm. The inhibition zone diameter of 30 μg/10 μg disk, susceptible isolates: 19.5 mm–31 mm, resistance isolates: 6.5 mm–11 mm. The inhibition zone diameter of ceftazidime (30 μg), susceptible isolates: 6.5 mm–27.5 mm, resistance isolates 6.5 mm.ConclusionOur results show that 30 μg/50 μg, 30 μg/25 μg, 30 μg/10 μg CAZ/AVI disk have significant statistical differences to determinate CAZ/AVI antibacterial activity, but for 30 μg/50 μg disk, there has a cross section between susceptible isolates (minimum 20.5 mm) and resistance isolates (maximum 21.5 mm). For 30 μg/25 μg disk, it is hard to distinguish the difference between susceptible isolates (minimum 19.7 mm) and resistance isolates (maximum 19.2 mm), so 30 μg/10 μg CAZ/AVI disk is more conducive to determinate antibacterial activity.
登录
查看更多内容
影响因子：
5.3
作者：
通讯作者：
--
影响因子：
4.2
作者：
Del Franco M;Paone L;Novati R;Giacomazzi CG;Bagattini M;Galotto C;Montanera PG;Triassi M;Zarrilli R
通讯作者：
Zarrilli R
DOI：
10.1016/j.diagmicrobio.2017.05.009
发表时间：
2017-08-01
影响因子：
2.9
作者：
Wenzler, Eric;Deraedt, Matthew F.;Danizger, Larry H.
通讯作者：
Danizger, Larry H.
影响因子：
19
作者：
Albiger, B.;Glasner, C.;Monnet, D. L.
通讯作者：
Monnet, D. L.
影响因子：
4.2
作者：
Guyomard-Rabenirina S;Malespine J;Ducat C;Sadikalay S;Falord M;Harrois D;Richard V;Dozois C;Laboratory working group;Breurec S;Talarmin A
通讯作者：
Talarmin A